Stock listing
CTOR Stock Price, News, Filings & Events — Citius Oncology, Inc.
Selected listing: CTOR · NASDAQ · USD · US
This page tracks Citius Oncology, Inc.'s CTOR:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following CTOR:NASDAQ. CTOR:NASDAQ is the stock-level entry point for investors researching Citius Oncology, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Citius Oncology, Inc. is a public company traded under the ticker CTOR in the American market. The company has a market capitalization of approximately $64.1 million. Citius Oncology focuses on developing innovative therapies for cancer treatment.
- Ticker
- CTOR:NASDAQ
- Asset type
- Stock
- Market cap
- $85.3M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- NASDAQ
- Currency
- USD
Citius Oncology, Inc. CTOR:NASDAQ stock context
This page tracks Citius Oncology, Inc.'s CTOR:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following CTOR:NASDAQ. CTOR:NASDAQ is the stock-level entry point for investors researching Citius Oncology, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Citius Oncology, Inc. is a public company traded under the ticker CTOR in the American market. The company has a market capitalization of approximately $64.1 million. Citius Oncology focuses on developing innovative therapies for cancer treatment.
Latest news from Citius Oncology, Inc.
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
August 14, 2026
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
August 12, 2026
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
August 5, 2026
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption
July 21, 2026
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pem...
June 1, 2026
Research Citius Oncology, Inc.
Citius Oncology, Inc. investor report
Review AI stock analysis and investor report context for CTOR:NASDAQ.
Citius Oncology, Inc. company profile
View the public company page for Citius Oncology, Inc. on 6ix.
Citius Oncology, Inc. news
Read company news and market updates connected to Citius Oncology, Inc..
Citius Oncology, Inc. investor events
Find investor webinars, events, and replay context for Citius Oncology, Inc..